Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • From 2007 to 2011, lung cancer incidence rates decreased by three percent each year in men and 2.2 percent each year in women.  
  • New cancer treatments account for large percent of life expectancy gains
     
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is for glioblastoma. The medicine singles out and latches onto the receptors on…  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…